(SNP) was studied on endothelium-denuded aortic rings. The effect of MTX on hind paw radiographic score, serum lipids and plasma pro-inflammatory cytokines (TNFα and IL-1β) levels was measured. Results: As compared to Vehicle rats, MTX significantly reduced arthritis score (p<0.01) but did not change radiographic score. It reduced plasma cytokines levels (p=0.02) but not total cholesterol and triglycerides levels. MTX did not change Ach-induced relaxation as compared to Vehicle. As regards endothelial pathways, MTX increased vascular NOS activity (p<0.0001) and decreased superoxide anions production but did change neither COX-2 and arginase activities nor EDHF production. Vascular smooth muscle reactivity to NE and SNP was unchanged by the treatment. Conclusions: Despite a reduction of clinical and biological inflammation, MTX did not improve endothelial function in AIA rats. The study of endothelial mechanisms highlights the role of COX and arginase as seminal targets for reducing ED in RA. This study suggests that other mechanisms than improvement of endothelial function are involved in the CV benefits of MTX in RA that remain to be elucidated. Our data also suggest that the adjunction of drugs targeting endothelial function to MTX in RA patients might improve their CV prognostic. Background: Anti-carbamylated protein antibodies (anti-CarP) are a new type of autoantibodies specific of patients with RA. Reactivity has generally been tested with in vitro carbamylated proteins from fetal calf serum (FCS) as anti-CarPF. It is likely that other sources of antigens could be more suitable than FCS unless the reactivity of the autoantibodies is directed primarily against the carbamylated residues independently of the protein.
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Conclusions

Objectives:
To evaluate the anti-CarP antibodies against in vitro carbamylated synovial tissue proteins (anti-CarPS) and to compare them with anti-CarPF antibodies. Methods: A pool of sinovial tissue proteins from 3 osteoarthritis patients was in vitro carbamylated and used as antigen for ELISA. Anti-CarPS antibodies were determined in 520 sera from patients with RA and 278 healthy controls, which have been previously tested for anti-CarPF antibodies (1). Logistic regression analysis was used to evaluate the association of the antibodies with SE alelles, PTPN22, smoking and erosions. Relationship between antibodies titers was analyzed with Spearman rank correlation (r s ) and concordance between positivity of the different antibodies was analyzed with the Goodman and Kruskal γ. Results: Similar percentages of patients were positive for anti-CarPS (31.7%) and for anti-CarPF antibodies (29.4%). However, many patients were discordant (28.9%). Notably, the concordance between anti-CarPS and anti-CCP antibodies was higher than the concordance between anti-CarPS and anti-CarPF antibodies (γ =0.73, respectively) . Moreover, titers of anti-CarPS antibodies were more correlated with anti-CCP than with anti-CarPF antibodies (r s =0.41, 95% CI: 0.33-0.48 vs. r s =0.29, 95% CI: 0.21-0.37, respectively). Accordingly, presence of anti-CarPS antibodies showed a clearer trend to be associated with the genetic and environmental RA risk factors than anti-CarPF antibodies, although only the association with smoking was significant (smoking OR=2.0, p=0.02 vs. OR=1.1, p=0.8, respectively; OR=1.3 vs. OR=1.1 for HLA-SE and OR=1.3 vs. OR=0.9 for PTPN22). There were no differences in the association with erosions, which was significant for both antibodies analyzed separately (OR=2.3, p=6.8 x 10 -4 for anti-CarPS and OR=2.4 p=2.0 x 10 -4 for anti-CarPF) and together (OR=1.8, p=0.02 and OR=2.0, p=0.005, respectively). Conclusions: Our results indicate that the proteins used as antigens in the determination of anti-CarP antibodies are relevant for the obtained positivity and titer. The differences could affect the pattern of characteristics associated with these antibodies, making it necessary to identify the specific carbamylated autoantigens targeted by them in vivo. 
